Summary
- Two new drugs, lecanemab and donanemab, are at the center of a major medical controversy surrounding their effectiveness in slowing down Alzheimer’s disease.
- Supporters believe these drugs offer a significant breakthrough in the fight against Alzheimer’s after years of research.
- Critics view these drugs as another letdown following numerous costly failures in the field.
- Renowned biologist John Hardy sees these treatments as a turning point in Alzheimer’s research.